-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 9, Golly Pharmaceuticals announced that China's National Medical Products Administration has approved the launch of ASC40 in the treatment of patients with moderate and severe acne phase II clinical trials
The Phase II study is a randomized, double-blind, placebo-controlled, multi-center clinical trial to be carried out in China to evaluate the safety and effectiveness of each dose group in the treatment of patients with moderate and severe acne vulgaris
Acne is the eighth most epidemic disease in the world, and the number of acne patients worldwide exceeds 640 million
The current first-line drugs for acne treatment include topical creams such as retinoic acid, androgen receptor inhibitors, oral isotretinoin and antibiotics
Fatty acid synthase (FASN) is a key enzyme in the pathway of regulating fatty acid de novo synthesis (DNL)
Note: The original text has been deleted